KMT5A and neoplasm: Since SET8 has been implicated in the development of a variety of cancers and the widespread use of cisplatin as a chemotherapeutic agent for most solid tumors, but with known nephrotoxicity, the results from this study suggest that combined administration of SET8 inhibitors with cisplatin could enhance tumor eradication while simultaneously protecting against AKI.